ライフサイエンスコーパス: Lyme disease vaccine

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 en rendered obsolete by the recombinant OspA Lyme disease vaccine.

2 suggests that DbpA may not be suitable as a Lyme disease vaccine.

3 implicate DBP as a new candidate for a human Lyme disease vaccine.

4 n important consideration in the design of a Lyme disease vaccine.

5 e successfully developed a second-generation Lyme disease vaccine.

6 es a basis for rational design of OspA-based Lyme disease vaccines.

7 articipants enrolled in a phase III trial of Lyme disease vaccine; 118 participants had erythema migr

8 ken to examine the cost-effectiveness of the Lyme disease vaccine and the factors that influence its

9 ol groups: 1) inflammatory arthritis but not Lyme disease vaccine (arthritis controls), 2) Lyme disea

10 A Lyme disease vaccine based on recombinant OspA has been

11 Recombinant Lyme disease vaccines based on purified preparations of

12 A Lyme disease vaccine, based on the Borrelia burgdorferi

13 yme disease vaccine (arthritis controls), 2) Lyme disease vaccine but not inflammatory arthritis (vac

14 ra from immune mice to identify new putative Lyme disease vaccine candidates.

15 m inflammatory arthritis had developed after Lyme disease vaccine (cases) were compared with 3 contro

16 effectiveness and cost-effectiveness of the Lyme disease vaccine in populations at various levels of

17 tor in determining the cost-effectiveness of Lyme disease vaccines in those areas.

18 The Lyme disease vaccine is based on the outer-surface lipop

19 The Lyme disease vaccine is cost-effective only for individu

20 These results suggest that Lyme disease vaccine is not a major factor in the develo

21 The antigenic component of a common Lyme disease vaccine is recombinant outer surface protei

22 arthritis (vaccine controls), and 3) neither Lyme disease vaccine nor inflammatory arthritis (normal

23 r surface protein (Osp) A has been used as a Lyme disease vaccine that blocks transmission: OspA anti

24 highlighting use of BBI39 proteins as novel Lyme disease vaccines that can target pathogens in the h

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。